Soligenix Inc. (NASDAQ: SNGX) has published new data demonstrating extended stability of its ebolavirus vaccines developed using the ThermoVax platform. According to a manuscript accepted by Vaccine, bivalent and trivalent vaccines formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens retained full potency after two years of storage at temperatures up to 40°C (104°F).
The thermostable vaccines, developed in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, have demonstrated robust immune responses in animal models, achieving up to 100% protection in non-human primates. This breakthrough addresses one of the most significant challenges in global vaccine distribution—the cold-chain requirement that limits accessibility in remote and tropical regions where ebolavirus outbreaks typically occur.
ThermoVax enhances protein subunit vaccines, which are considered the gold standard for safety, by eliminating the need for refrigeration during storage and transport. This technology could dramatically improve vaccine distribution capabilities in developing countries and enhance global pandemic preparedness efforts. The stability data suggests these vaccines could be deployed effectively in regions with limited infrastructure, potentially saving countless lives during future outbreaks.
The development of these vaccine programs has been supported by government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. Additional information about Soligenix's developments is available in the company's newsroom at https://ibn.fm/SNGX.
This advancement represents a significant step forward in biopharmaceutical technology, particularly for rare disease treatments and public health solutions. The ability to maintain vaccine potency under challenging environmental conditions could transform how medical interventions are delivered in crisis situations, making effective treatments more accessible to populations most vulnerable to infectious disease outbreaks.
